Fenretinide: Prevenção em Pacientes Tratadas de Carcinoma de Mama
A Fenretinide (HPR) é um retinóide sintético análogo á Vit. A que provou ser efetivo na prevenção de tumores mamários em animais modelos. Este estudo, nesta fase 1, foi proposto no Instituto Nacional dos Tumores de Milão com o objetivo de avaliar a tolerância desta droga em humanos. Neste estudo, 1...
Main Authors: | A. Costa, M. A. G. Gonçalves, A. Frasson, C. Andreoli, F. Buranelli, T. Campa, F. Formelli, A. Magni, M. Pizzichetta |
---|---|
Format: | Article |
Language: | English |
Published: |
Instituto Nacional de Câncer (INCA)
2023-08-01
|
Series: | Revista Brasileira de Cancerologia |
Subjects: | |
Online Access: | https://rbc.inca.gov.br/index.php/revista/article/view/3242 |
Similar Items
-
Retinoids Delivery Systems in Cancer: Liposomal Fenretinide for Neuroectodermal-Derived Tumors
by: Veronica Bensa, et al.
Published: (2021-08-01) -
A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model
by: Orienti I, et al.
Published: (2019-12-01) -
Preparation and Characterization of Amorphous Solid Dispersions for the Solubilization of Fenretinide
by: Guendalina Zuccari, et al.
Published: (2023-03-01) -
Fenretinide Acts as Potent Radiosensitizer for Treatment of Rhabdomyosarcoma Cells
by: Eva Brack, et al.
Published: (2021-06-01) -
Fenretinide in Cancer and Neurological Disease: A Two-Face Janus Molecule
by: Rosa Luisa Potenza, et al.
Published: (2022-07-01)